Herbas VPB

Spausdinti
EN | LT
LT - COMBINED USE OF MARIZOMIB AND BEVACIZUMAB FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS
EN - COMBINED USE OF MARIZOMIB AND BEVACIZUMAB FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS

Teisinis statusas

Patentas neįsigaliojo (pagal EPK)

Bibliografiniai duomenys
Tarptautinės patentų klasifikacijos indeksai (TPK)
(51) INT.CL. A61K 39/395 (2006.01)
A61K 39/3955 (2013.01)
A61K 31/407 (2006.01)
A61K 31/495 (2013.01)
A61K 31/495 (2006.01)
C07K 16/22 (2013.01)
C07K 16/2896 (2013.01)
A61P 35/00 (2006.01)
A61P 35/02 (2006.01)
C07K2317/21 (2013.01)
C07K2317/24 (2013.01)
C07K2317/73 (2013.01)
A61K 31/407 (2013.01)
A61K2039/545 (2013.01)
A61N2005/1098 (2013.01)
A61P 35/00 (2018.01)
A61P 35/02 (2018.01)
Europos patentas
(11) Patento numeris 3463458
(13) Dokumento rūšis T
(96) Europos patento paraiškos numeris 17730628.9
Europos patento paraiškos padavimo data 2017-06-01
(97) Europos patento paraiškos paskelbimo data 2019-04-10
(45) Paskelbimo apie Europos patento išdavimą data 2024-04-10
(46) Apibrėžties vertimo paskelbimo data
Tarptautinės paraiškos padavimo
(86) Numeris PCT/US2017/035504
Data 2017-06-01
Tarptautinės paraiškos paskelbimo
(87) Numeris WO 2017/210463
Data 2017-12-07
Prioriteto paraiškos
(30) Numeris Data Šalis
201662344194 P 2016-06-01 US
201662349491 P 2016-06-13 US
201662362845 P 2016-07-15 US
201662374136 P 2016-08-12 US
201662418466 P 2016-11-07 US
201662424178 P 2016-11-18 US
201762471321 P 2017-03-14 US
201762490528 P 2017-04-26 US
201762491943 P 2017-04-28 US
Išradėjai
(72)
TRIKHA, Mohit , US
LEVIN, Nancy , US
MACLAREN, Ann , US
Savininkas
(73) Celgene Tri A Holdings Ltd. , Aon House 30 Woodbourne Avenue, Pembroke HM 08, BM
Trikha, Mohit , 3366 N. Torrey Pines Court 210, La Jolla, California 92037, US
Levin, Nancy , 3366 N. Torrey Pines Court 210, La Jolla, California 92037, US
Maclaren, Ann , 3366 N. Torrey Pines Court 210, La Jolla, California 92037, US
Pavadinimas
(54) COMBINED USE OF MARIZOMIB AND BEVACIZUMAB FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS
  COMBINED USE OF MARIZOMIB AND BEVACIZUMAB FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) CANCERS